Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics of Dasotraline in Hepatic Dysfunction
NCT02795637Phase 1Completed
- Sponsor
- Sumitomo Pharma America
- Start
- May 2016
- Primary completion
- Nov 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of dasotraline in attention deficit hyperactivity disorder (ADHD) and binge eating disorder (BED) (4 arms), sponsored by Sumitomo Pharma America. Primary endpoints: Area under the plasma/serum concentration-time curve from time zero to infinity and Time of occurrence of Cmax. Started May 2016; status: completed.
02
Drugs
dasotraline
03
Conditions
attention deficit hyperactivity disorder (ADHD)binge eating disorder (BED)
Beyond the preview
Go deeper on NCT02795637.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02795637.